Gene · 887
CCKBR: cholecystokinin B receptor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CCKBR: cholecystokinin B receptor. Genes, record 887. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/887
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P32239 | Gastrin/cholecystokinin type B receptor | 447 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents52
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 41194 | P32239 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 5940 | P32239 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 755 | P32239 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 755 | P32239 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 5940 | P32239 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 25956 | P32239 | Espacenet |
| EP 4487869 A2 | 2025-01-08 | 203 | P32239 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 25956 | P32239 | Espacenet |
| KR 1020240027895 A | 2024-03-04 | 395 | P32239 | Espacenet |
| JP 2023058610 A | 2023-04-25 | 25956 | P32239 | Espacenet |
1 to 10 of 52
See all 52 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| CI-988 | CHEMBL2062154 | Cholecystokinin B receptor antagonist | ANTAGONIST | ChEMBL |
| ITRIGLUMIDE | CHEMBL1256717 | Cholecystokinin B receptor antagonist | ANTAGONIST | ChEMBL |
| NETAZEPIDE | CHEMBL324547 | Cholecystokinin B receptor antagonist | ANTAGONIST | ChEMBL |
| PROGLUMIDE | CHEMBL316561 | Cholecystokinin receptor antagonist | ANTAGONIST | ChEMBL |
Trials9
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06017323 | PROGLUMIDE | PHASE1 | ClinicalTrials.gov | |
| NCT05827055 | PROGLUMIDE | PHASE2 | ClinicalTrials.gov | |
| NCT05551858 | PROGLUMIDE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT04152473 | PROGLUMIDE | PHASE1 | ClinicalTrials.gov | |
| NCT02620696 | NETAZEPIDE | PHASE1 | ClinicalTrials.gov | |
| NCT02597712 | NETAZEPIDE | PHASE2 | 2021-04-12 | ClinicalTrials.gov |
| NCT01444014 | NETAZEPIDE | PHASE2 | ClinicalTrials.gov | |
| NCT01339169 | NETAZEPIDE | PHASE2 | ClinicalTrials.gov | |
| NCT01298999 | NETAZEPIDE | PHASE2 | 2021-11-23 | ClinicalTrials.gov |
NIH grants1,011
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CCKBR papers | Newest fiscal year |
|---|---|---|---|
| P30CA051008 | Georgetown University Lombardi Comprehensive Cancer Center Support Grant | 10 | 2025 |
| P30CA023074 | University of Arizona Cancer Center - Cancer Center Support Grant | 5 | 2025 |
| T32GM008562 | Clinical Pharmacology Training Program | 5 | 2025 |
| ZIADK053100 | Characterization And Pharmacology Of Receptors For Gastrointestinal Peptides | 5 | 2025 |
| ZIADK053101 | Cellular Basis Of Action Of Gastrointestinal Peptides/Growth factors | 5 | 2025 |
| P30CA013696 | Cancer Center Support Grant | 4 | 2025 |
| P30CA056036 | Translational Research in Cancer | 4 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 4 | 2025 |
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 4 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 3 | 2025 |
1 to 10 of 1,011Source NIH's project files
See all 1,011 nih grantsPapers2,046
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Autoimmune gastritis diverges from a shared corpus origin: molecular reconstruction of the adenocarcinoma axis and clinical anchoring of the neuroendocrine axis. | Front Immunol | 2026 | 42712509 | PubTator, text mining | PubMed |
| Novel nastorazepide-based radioligands demonstrate effective cholecystokinin-2 receptor targeting with potential for theranostic applications. | Theranostics | 2026 | 42707991 | PubTator, text mining | PubMed |
| Targeted radionuclide-drug conjugates: Current status and perspectives. | Eur J Med Chem | 2026 | 42520735 | PubTator, text mining | PubMed |
| Therapeutic potential of pachymic acid in glioma: a comprehensive approach combining experimental validation, network pharmacology, and machine learning. | Brain Res | 2026 | 42468874 | PubTator, text mining | PubMed |
| Immune and clinicopathological features of molecularly defined prolactinoma subtypes. | J Neurosurg | 2026 | 42361377 | PubTator, text mining | PubMed |
| Development of Novel Cholecystokinin 2 Receptor-Targeted Radioligand Containing Albumin Binder for Efficient 111In/177Lu Theranostics. | Bioconjug Chem | 2026 | 42283376 | PubTator, text mining | PubMed |
| Effects of Lacticaseibacillus paracasei HP7 Against Helicobacter pylori-Induced Gastric Mucosal Inflammation and Mucosal Protection. | J Med Food | 2026 | 41870161 | PubTator, text mining | PubMed |
| A progressive fine-tuning framework with dynamic parameter selection for low-resource peptide-GPCR interaction prediction. | Brief Bioinform | 2026 | 41838876 | PubTator, text mining | PubMed |
| Integrated network toxicology and computational profiling of acetyl tributyl citrate-related mechanisms in Alzheimer's disease. | J Alzheimers Dis | 2026 | 41823681 | PubTator, text mining | PubMed |
| Gastrin ameliorates heart failure and suppresses myocardial remodeling via the JAK2/STAT3 and ERK1/2 pathways. | PLoS One | 2026 | 41785239 | PubTator, text mining | PubMed |
1 to 10 of 2,046
See all 2,046 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/887
GET https://conductscience.org/api/genes/v1/887/patents?page=2